Yiming Medicine: The stock has deviated from the value for two consecutive days, with a cumulative increase of more than 20%, warning of trading risks.

Yiming Pharmaceuticals announced that the company's stock price had a deviation of more than 20% for two consecutive trading days on July 1st and July 2nd, 2026, which was considered abnormal volatility. After self-inspection, the company found that there was no need to correct or supplement previous information, no significant undisclosed information, normal operations, no undisclosed matters regarding the controlling shareholder or actual controller, no trading of company stocks during the abnormal volatility period, and no violation of fair disclosure regulations. The company reminds investors to pay attention to trading risks and designates the Securities Times, Securities Daily, and Juchao Information Network as the designated disclosure media.